%PDF-1.4
%
108 0 obj
<>
endobj
173 0 obj
<>/Font<>>>/Fields[]>>
endobj
105 0 obj
<>
endobj
58 1 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-13T19:13:27Z
2024-03-28T12:40:24-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T12:40:24-07:00
application/pdf
Heather
2001-908.nov02
uuid:a548dc12-1dd1-11b2-0a00-f809275d6100
uuid:a548dc1a-1dd1-11b2-0a00-aa0000000000
endstream
endobj
92 0 obj
<>
endobj
94 0 obj
<>
endobj
93 0 obj
<>
endobj
109 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 66 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 68 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 70 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 72 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 74 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 76 0 R/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 78 0 R/Type/Page>>
endobj
49 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 80 0 R/Type/Page>>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 82 0 R/Type/Page>>
endobj
55 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 84 0 R/Type/Page>>
endobj
214 0 obj
[218 0 R]
endobj
215 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(control of disease progression within our grasp? Review of the)Tj
0 -1.25 TD
[(GRISAR study)64.8 (. Gruppo Reumatologi Italiani Studio )54.8 (Artrite)]TJ
T*
(Reumatoide. Br J Rheumatol 1996;35 Suppl 2:8-13.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Mottonen )17.7 (T)74 (,)-0.1 ( Hannonen P)110.7 (, Leirisalo-Repo M, et al. Comparison of)]TJ
2.175 -1.25 Td
(combination therapy with single-drug therapy in early rheumatoid)Tj
T*
(arthritis: a randomised trial. FIN-RACo trial group. Lancet)Tj
0 Tc 0 Tw T*
(1999;353:1568-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (Kim JM, )17.7 (W)79.9 (eisman MH. )17.7 (When does rheumatoid arthritis begin and)]TJ
2.175 -1.25 Td
[(why do we need to know? )54.8 (Arthritis Rheum 2000;43:473-84.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (T)35 (unn EJ, Bacon P)91.7 (A. Dif)17.7 (ferentiating persistent from self-limiting)]TJ
2.175 -1.25 Td
(symmetrical synovitis in an early arthritis clinic. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1993;32:97-103.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875.1 (Machold KP)110.7 (, Eberl G, Leeb BF)79.7 (, Nell )17.7 (V)128.9 (,)-0.1 ( )17.7 (W)39.9 (indisch B, Smolen JS.)]TJ
2.175 -1.25 Td
(Early arthritis therapy: rationale and current approach. J Rheumatol)Tj
0 Tc T*
(1998;25 Suppl 53:13-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
0 Tc -2.175 -1.25 Td
[(37.)-875 (Ropes MW)91.8 (, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958)]TJ
-0.00011 Tc 2.175 -1.25 Td
(revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum)Tj
T*
(Dis 1958;9:175-6.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (Pincus )17.7 (T)74 (, Brooks RH, Callahan LF)79.7 (. )54.8 (A)-220.1 (proposed 30-45 minute 4)]TJ
2.175 -1.25 Td
(page standard protocol to evaluate rheumatoid arthritis that includes)Tj
T*
[(measures of inflammatory activity)64.8 (, joint damage, and longterm)]TJ
T*
(outcomes. J Rheumatol 1999;26:473-80.)Tj
-2.175 -1.25 Td
[(39.)-875.1 (Fuchs HA, Brooks RH, Callahan LF)79.7 (, Pincus )17.7 (T)74 (.)-0.1 ( )54.8 (A)-220.1 (simplified )]TJ
2.175 -1.25 Td
(twenty-eight-joint quantitative articular index in rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 1989;32:531-7.)]TJ
-2.175 -1.25 Td
[(40.)-875.1 (Smolen JS, Breedveld FC, Eberl G, et al. )17.7 (V)110.8 (alidity and reliability of)]TJ
2.175 -1.25 Td
(the twenty-eight-joint count for the assessment of rheumatoid)Tj
T*
[(arthritis activity)64.8 (. )54.8 (Arthritis Rheum 1995;38:38-43.)]TJ
-2.175 -1.25 Td
[(41.)-875.1 (Singer F)79.7 (, Kolarz G, Mayrhofer F)79.7 (, Scherak O, )17.7 (Thumb N. )17.7 (The use of)]TJ
2.175 -1.25 Td
(questionnaires in the evaluation of the functional capacity in)Tj
T*
(rheumatoid arthritis. Clin Rheumatol 1982;1:251-61.)Tj
-2.175 -1.25 Td
[(42.)-875.1 (Erlacher L, )17.7 (W)39.9 (intersber)17.7 (ger )17.7 (W)91.8 (, Menschik M, et al. Reactive arthritis:)]TJ
2.175 -1.25 Td
(urogenital swab culture is the only useful diagnostic method for the)Tj
T*
(detection of the arthritogenic infection in extra-articularly)Tj
T*
[(asymptomatic patients with undif)17.7 (ferentiated oligoarthritis. Br J)]TJ
T*
(Rheumatol 1995;34:838-42.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (Larsen )54.8 (A, Dale K, Eek M. Radiographic evaluation of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis and related conditions by standard reference films. )54.8 (Acta)]TJ
T*
(Radiol Diagnos 1977;18:481-91.)Tj
30.825 51.25 Td
[(44.)-875.1 (Harrison BJ, Symmons DPM, Barrett EM, Silman )54.8 (AJ. )17.7 (The)]TJ
2.175 -1.25 Td
[(performance of the 1987 )54.8 (ARA)-220.2 (classification criteria for rheumatoid)]TJ
T*
(arthritis in a population based cohort of patients with early )Tj
T*
(inflammatory polyarthritis. J Rheumatol 1998;28:2324-30.)Tj
-2.175 -1.25 Td
[(45.)-875.1 (Brackertz D, )17.7 (V)59.8 (ischer )17.7 (TL. OM-8980 in rheumatoid arthritis:)]TJ
2.175 -1.25 Td
[(A)-220.1 (6-month double blind placebo controlled multicenter study)64.8 (. )]TJ
T*
(J Rheumatol 1989;16:19-23.)Tj
-2.175 -1.25 Td
[(46.)-875.1 (Prevoo MLL, van \324t Hof MA, Kuper HH, van de Putte LBA, van)]TJ
2.175 -1.25 Td
(Riel PLCM. Modified disease activity scores that include)Tj
T*
[(twenty-eight-joint counts. )54.8 (Arthritis Rheum 1995;38:44-8.)]TJ
-2.175 -1.25 Td
[(47.)-875.1 (Huizinga )17.7 (TW)91.7 (, Machold KP)110.7 (, Breedveld FC, Lipsky PE, Smolen JS.)]TJ
2.175 -1.25 Td
[(Criteria for early rheumatoid arthritis: from Bayes\325)-201.1 (law revisited to)]TJ
T*
[(new thoughts on pathogenesis. )54.8 (Arthritis Rheum 2002;46:1)36.8 (155-9.)]TJ
-2.175 -1.25 Td
[(48.)-875.1 (Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of)]TJ
2.175 -1.25 Td
(mild, early inflammatory arthritis: the importance of disease)Tj
T*
[(duration, rheumatoid factor)39.7 (, and the shared epitope. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2184-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(49.)-875.1 (Stenger )54.8 (AA, van Leeuwen MA, Houtman PM, et al. Early ef)17.7 (fective)]TJ
2.175 -1.25 Td
(suppression of inflammation in rheumatoid arthritis reduces)Tj
T*
[(radiographic progression. Br J Rheumatol 1998;37:1)36.7 (157-63.)]TJ
-2.175 -1.25 Td
[(50.)-875.1 (Hueber )17.7 (W)91.8 (, Hassfeld )17.7 (W)91.8 (, Smolen JS, Steiner G. Sensitivity and)]TJ
2.175 -1.25 Td
(specificity of anti-Sa autoantibodies for rheumatoid arthritis.)Tj
T*
(Rheumatology 1999;38:155-9.)Tj
-2.175 -1.25 Td
[(51.)-875.1 (Cush JJ, Lipsky PE, Postlethwaite )54.8 (AE, Schrohenloher RE, Saway)]TJ
2.175 -1.25 Td
[(A, Koopman )17.7 (WJ. Correlation of serologic indicators of )]TJ
T*
[(inflammation with ef)17.7 (fectiveness of nonsteroidal antiinflammatory)]TJ
T*
[(drug therapy in rheumatoid arthritis. )54.8 (Arthritis Rheum 1990;)]TJ
0 Tc 0 Tw T*
(33:19-28.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(52.)-875.1 (Alarcon GS, Schrohenloher RE, Bartolucci )54.8 (AA, )17.7 (W)79.9 (ard JR, )17.7 (W)39.9 (illiams)]TJ
2.175 -1.25 Td
[(HJ, Koopman )17.7 (WJ. Suppression of rheumatoid factor production by)]TJ
T*
(methotrexate in patients with rheumatoid arthritis. Evidence for)Tj
T*
[(dif)17.7 (ferential influences of therapy and clinical status on IgM and)]TJ
T*
[(IgA)-220.2 (rheumatoid factor expression. )54.8 (Arthritis Rheum 1990;)]TJ
0 Tc 0 Tw T*
[(33:1)36.9 (156-61.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(53.)-875.1 (Sharp JT)73.9 (, )17.7 (W)79.9 (olfe F)79.7 (, Mitchell DM, Bloch DA. )17.7 (The progression of)]TJ
2.175 -1.25 Td
(erosion and joint space narrowing scores in rheumatoid arthritis)Tj
T*
[(during the first twenty-five years of disease. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:660-8.)Tj
ET
0 0 0 0 k
431 777 126 -27 re
f*
428 770 130 -25 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Machold, et al: V)110.7 (e)0.1 (ry r)36.8 (ecent onset arthritis)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2287)Tj
ET
0 0 0 0 k
/GS0 gs
101.67 59.08 407.5 -10.83 re
f*
0.5 w
101.67 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
84 0 obj
<>stream
8;Z\7!KP&O#ikq,j?#<&_);U6HW,!`8[2%(X[rg9ltYr-)d`hs!M>DlEHs4[osOe5
\3/203nBAJm8*GaBSNYZ5T_X'=R8h/,#++PN)sP4jP?DA?Oc\:e%CAh,ZrUl/0a+F
.rH4;-\oP9aH]80%^qC'`X4j`R=Z6K0$77YcKdjtAN"M.D.&^d1sNGD?je2^$HDG+
M41Qd/t*H_3*m@:K7KgF)Z"%_4?>UK>H4,p/--\kGbA8/\X5;P-\O)I=O:J\bjJ4WPGNcQ/4KDnB`D
lI.`ZY.Dqqn988oL0:uMiV#`U1.AFdO4"Z5q@<\af\"j/f\"jO(>&k:-H^VPVon$1
%/k
endstream
endobj
90 0 obj
[/Indexed/DeviceRGB 255 89 0 R]
endobj
89 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
117 0 obj
<>
endobj
111 0 obj
<>
endobj
150 0 obj
<>
endobj
181 0 obj
<>
endobj
112 0 obj
<>
endobj
140 0 obj
<>stream
HTiPSY~KA@PظL+JKku "!H$ I YQ@@\ZQQKTdʙ'kz~LݪnsW;uχcfswiP$nF%
c>7|uyf|k>2~}&q,E/eYv>OG2T 0[ĈS)QRAx&&2j%L@"HI3E?u%L#MR3}X*K0[)T'IcQ)B?t|7fa3V*HaV1,.b=01#1o`oQ
@TCQc5@qr]=E)EnՌ=3|f_,sfqfnyoVf~mdiss.۟朤R;ܮܝsۻpttw?įIsCt
42Z2
Z
ar
.
gV)Բ^xY>y;(ĸ,jEIyf¾:&*r"d>KIWe:Nݸ;;f+
(#sȆ>s
%JYvn^~BZ)IeJ2Yj P$t6(y;$sxL`xMz}kk^,NM\.D%FS~쒑K#^iku͗F:=ht_3[tzV).{ġm:9l@d"?(Ux>*r3l LRb-oDta#Y:Cyh:1HU팘|rWV!?k횲#eμG8 s䡅R>|7U:8_w7%"K.@dV!/UTtk]?,l<泋 ځ蔽X.O9C(a)[txq
NJRI
2%ʓ@d[-B6y¬xPO|(
9 [`?j5'_|:뵽0(:_Sq>q]7ӫI@ v
M>oat (hڗF
/Hb:-6Ѩʂa
JF~[6)aT-8PY٥P
xz^C:g`N7 I\kye|{vBӟ+;#b`g[S\%++EY.